Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: Hepatology. 2023 Apr 17;77(5):1580–1592. doi: 10.1002/hep.32744

FIGURE 3.

FIGURE 3

Exogenous IL-33 promotes liver regeneration in IL-33−/− mice after PHx. (A) Strategy of exogenous IL-33 treatments in IL-33−/− and ST2−/− mice after PHx. (B,C) Ki67 immunostaining was performed in liver sections of IL-33−/− mice with PBS or recombinant murine IL-33 (rmIL-33) treatment at 36 h after PHx (scale bar: 100 μm). Ki67-positive hepatocytes were quantified (n = 4/group). (D) The ratios of liver/body weight were analyzed at 36 h after PHx (n = 4/group). (E,F) Ki67 immunostaining was performed in liver sections of ST2−/− mice with PBS or rmIL-33 treatment at 36 h after PHx (scale bar: 100 μm). Ki67-positive hepatocytes were quantified (n = 5/group). (G) The ratios of liver/body weight were analyzed at 36 h after PHx (n = 5/group). Two-tailed unpaired Student’s t test was performed in (C), (D), (F), and (G)